Your browser doesn't support javascript.
loading
Harmonising patient-access programmes: the Dutch DRUG Access Protocol platform.
Zeverijn, Laurien J; van Waalwijk van Doorn-Khosrovani, Sahar Barjesteh; van Roy, Anke A M G Pisters; Timmers, Lonneke; Ly Tran, T H; de Boer, Jolanda E; de Wit, Gijsbrecht F; Geurts, Birgit S; Gelderblom, Hans; Verheul, Henk M W; Blijlevens, Nicole; Wymenga, A N Machteld; Eskens, Ferry A L M; Smit, Egbert F; Bloemendal, Haiko J; Voest, Emile E.
Afiliação
  • Zeverijn LJ; Division of Molecular Oncology and Immunology, Netherlands Cancer Institute, 1066 CX Amsterdam, Netherlands; Oncode Institute, Utrecht, Netherlands.
  • van Waalwijk van Doorn-Khosrovani SB; CZ Health Insurance, Tilburg, Netherlands.
  • van Roy AAMGP; CZ Health Insurance, Tilburg, Netherlands.
  • Timmers L; National Health Care Institute (Zorginstituut Nederland), Diemen, Netherlands.
  • Ly Tran TH; National Health Care Institute (Zorginstituut Nederland), Diemen, Netherlands.
  • de Boer JE; National Health Care Institute (Zorginstituut Nederland), Diemen, Netherlands.
  • de Wit GF; Division of Molecular Oncology and Immunology, Netherlands Cancer Institute, 1066 CX Amsterdam, Netherlands; Oncode Institute, Utrecht, Netherlands.
  • Geurts BS; Division of Molecular Oncology and Immunology, Netherlands Cancer Institute, 1066 CX Amsterdam, Netherlands; Oncode Institute, Utrecht, Netherlands.
  • Gelderblom H; Department of Medical Oncology, Leiden University Medical Center, Leiden, Netherlands.
  • Verheul HMW; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, Netherlands.
  • Blijlevens N; Department of Hematology, Radboud University Medical Center, Nijmegen, Netherlands.
  • Wymenga ANM; Department of Medical Oncology, Medical Spectrum Twente, Enschede, Netherlands.
  • Eskens FALM; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, Netherlands.
  • Smit EF; Department of Thoracic Oncology, Netherlands Cancer Institute, 1066 CX Amsterdam, Netherlands; Department of Pulmonary Diseases, Leiden University Medical Center, Leiden, Netherlands.
  • Bloemendal HJ; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, Netherlands.
  • Voest EE; Division of Molecular Oncology and Immunology, Netherlands Cancer Institute, 1066 CX Amsterdam, Netherlands; Oncode Institute, Utrecht, Netherlands. Electronic address: e.voest@nki.nl.
Lancet Oncol ; 23(2): 198-201, 2022 02.
Article em En | MEDLINE | ID: mdl-35114116
Assuntos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Acessibilidade aos Serviços de Saúde / Antineoplásicos Aspecto: Determinantes_sociais_saude Limite: Humans País/Região como assunto: Europa Idioma: En Revista: Lancet Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Holanda
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Acessibilidade aos Serviços de Saúde / Antineoplásicos Aspecto: Determinantes_sociais_saude Limite: Humans País/Região como assunto: Europa Idioma: En Revista: Lancet Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Holanda